|
A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint. |
|
|
Honoraria - Amgen; Bayer; Dendreon; Janssen; Medivation; Sanofi |
Consulting or Advisory Role - Amgen; Dendreon; Janssen; Medivation; Sanofi |
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); GTx (Inst); ImClone Systems (Inst); Janssen (Inst); Oncogenex (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dendreon; Janssen; Medivation |
|
|
|
Stock and Other Ownership Interests - GTx |
|
|
|
|
|
Stock and Other Ownership Interests - Nymox; Sophiris Bio |
|
Consulting or Advisory Role - Medivation/Astellas |
Speakers' Bureau - Dendreon; Medivation/Astellas |
Research Funding - Advaxis (Inst); American Medical Systems (Inst); Bayer (Inst); Boston Scientific (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Nymox (Inst); Sophiris Bio (Inst) |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - GTx |